CAR-T and TIL therapies face hurdles in treating solid tumors

This narrative review looks at new cell therapies for hematologic malignancies and solid tumors. The authors discuss CAR-T therapy, TIL therapy, and T Cell Engagers (TCEs). They explain why these treatments face specific challenges when applied to solid tumors. The hostile tumor microenvironment often blocks CAR-T cells from working effectively. TIL therapy is hindered by complex biomanufacturing logistics and variable tumor immunogenicity. TCEs face challenges regarding persistence within the body. The review does not report specific safety concerns or serious adverse events from clinical trials. It notes that on-target off-tumor toxicity is a known risk for these therapies. The main reason to be careful is that current data are limited to narrative reviews rather than large clinical trials. Readers should understand that the future of curative regimens likely lies in rational combinatorial strategies. This means combining these therapies with other treatments may be necessary to overcome current limitations. The evidence is early and based on expert opinion rather than randomized data. Patients should wait for more practice-changing data before expecting these therapies to become standard care for solid tumors.